Paper28763548
Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
Lv J and 27 others. JAMA, 2017. Cited by 441 papers, by iCite.
Cite this record
ConductScience Library. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. Papers, record 28763548. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28763548
- Disease
- IgA glomerulonephritis73 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glomerulonephritis, IGA | Major topic |
| Glucocorticoids | Major topic |
| Infections | Major topic |
| Methylprednisolone | Major topic |
| Administration, Oral | |
| Adult | |
| Double-Blind Method | |
| Female | |
| Glomerular Filtration Rate | |
| Humans | |
| Kidney Failure, Chronic | |
| Male | |
| Middle Aged | |
| Proteinuria |
Source PubMed
Trials5
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT01560052 | Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study) | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT03468972 | Effect of Immunosuppression in IgA Nephropathy | Results | ClinicalTrials.gov | |
| NCT04662723 | Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. | Results | ClinicalTrials.gov | |
| NCT04833374 | Steroids Therapy in IgA Nephropathy With Crescents | Results | ClinicalTrials.gov | |
| NCT05528991 | Oxford Classification and Clinical Remission After Initial Treatments in Patients With IgA Nephropathy | Background | ClinicalTrials.gov |
Comments and corrections4
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 28763530 | Corticosteroids for IgA Nephropathy: TESTING for Benefit, Discovering Harm. | https://conductscience.org/library/papers/28763530 | PubMed |
| Comment in | 29159384 | In patients with proteinuric IgA nephropathy, benefits of methylprednisolone were offset by harms. | https://conductscience.org/library/papers/29159384 | PubMed |
| Comment in | 29203129 | Corticosteroids in IgA Nephropathy. | https://conductscience.org/library/papers/29203129 | PubMed |
| Comment in | 29237704 | TESTING Corticosteroids in IgA Nephropathy: A Continuing Challenge. | https://conductscience.org/library/papers/29237704 | PubMed |
References23
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17513327 | IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. | J Am Soc Nephrol | 2007 | https://conductscience.org/library/papers/17513327 | PubMed |
| 2 | 17978307 | Remission of proteinuria improves prognosis in IgA nephropathy. | J Am Soc Nephrol | 2007 | https://conductscience.org/library/papers/17978307 | PubMed |
| 3 | 9217756 | Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) | Lancet | 1997 | https://conductscience.org/library/papers/9217756 | PubMed |
| 4 | 22539830 | Corticosteroid therapy in IgA nephropathy. | J Am Soc Nephrol | 2012 | https://conductscience.org/library/papers/22539830 | PubMed |
| 5 | 18221258 | Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China. | Nephrology (Carlton) | 2008 | https://conductscience.org/library/papers/18221258 | PubMed |
| 6 | 2822795 | Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man. | J Hypertens | 1987 | https://conductscience.org/library/papers/2822795 | PubMed |
| 7 | 26630142 | Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26630142 | PubMed |
| 8 | 19414839 | A new equation to estimate glomerular filtration rate. | Ann Intern Med | 2009 | https://conductscience.org/library/papers/19414839 | PubMed |
| 9 | 10093981 | Corticosteroids in IgA nephropathy: a randomised controlled trial. | Lancet | 1999 | https://conductscience.org/library/papers/10093981 | PubMed |
| 10 | 19571791 | The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. | Kidney Int | 2009 | https://conductscience.org/library/papers/19571791 | PubMed |
| 11 | 23782179 | IgA nephropathy. | N Engl J Med | 2013 | https://conductscience.org/library/papers/23782179 | PubMed |
| 12 | 19628647 | Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. | Nephrol Dial Transplant | 2009 | https://conductscience.org/library/papers/19628647 | PubMed |
| 13 | 25677392 | Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study. | J Am Soc Nephrol | 2015 | https://conductscience.org/library/papers/25677392 | PubMed |
| 14 | 18930568 | Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. | Am J Kidney Dis | 2009 | https://conductscience.org/library/papers/18930568 | PubMed |
| 15 | 24892770 | Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. | JAMA | 2014 | https://conductscience.org/library/papers/24892770 | PubMed |
| 16 | 27032886 | Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis. | Am J Kidney Dis | 2016 | https://conductscience.org/library/papers/27032886 | PubMed |
| 17 | 25441437 | GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. | Am J Kidney Dis | 2014 | https://conductscience.org/library/papers/25441437 | PubMed |
| 18 | 28363480 | Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. | Lancet | 2017 | https://conductscience.org/library/papers/28363480 | PubMed |
| 19 | 21965586 | Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. | Nephrol Dial Transplant | 2012 | https://conductscience.org/library/papers/21965586 | PubMed |
| 20 | 24408121 | Progression of IgA nephropathy under current therapy regimen in a Chinese population. | Clin J Am Soc Nephrol | 2014 | https://conductscience.org/library/papers/24408121 | PubMed |
Cited by279
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 441 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42983718 | IgA nephropathy in a patient with 17α-hydroxylase/17,20-lyase deficiency caused by the CYP17A1 p. Y329fs mutation: a case report and review. | BMC Pediatr | 2026 | https://conductscience.org/library/papers/42983718 | PubMed |
| 42968938 | Targeted-Release Budesonide in Chinese Patients with IgA Nephropathy: A Real-World Retrospective Cohort Study. | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/42968938 | PubMed |
| 42898794 | Corticosteroids, serum proteins, and the next phase of precision medicine in IgA nephropathy. | Clin Kidney J | 2026 | https://conductscience.org/library/papers/42898794 | PubMed |
| 42756489 | Clinical remission trajectories and histopathological associations in patients with IgA nephropathy treated with targeted-release budesonide: a real-world cohort study. | Front Immunol | 2026 | https://conductscience.org/library/papers/42756489 | PubMed |
| 42709324 | Effectiveness and Safety of Nefecon in Primary IgA Nephropathy Across Different Baseline Proteinuria Levels: A Real-World Study. | Adv Ther | 2026 | https://conductscience.org/library/papers/42709324 | PubMed |
| 42688466 | Efficacy and safety of Nefecon, glucocorticoids, or supportive therapyadded to RASi+SGLT2i in IgA nephropathy. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42688466 | PubMed |
| 42675083 | Large language models decode narrative pathology reports to define clinically relevant subtypes in IgA nephropathy. | Nat Commun | 2026 | https://conductscience.org/library/papers/42675083 | PubMed |
| 42621401 | Telitacicept for IgA nephropathy: a systematic review and meta-analysis of observational studies. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42621401 | PubMed |
| 42523835 | Case Report: Successful telitacicept treatment for IgA nephropathy with stage 4 chronic kidney disease and acute renal failure. | Front Immunol | 2026 | https://conductscience.org/library/papers/42523835 | PubMed |
| 42483540 | IgA nephropathy management: what does the future hold? | Kidney Int Suppl (2011) | 2026 | https://conductscience.org/library/papers/42483540 | PubMed |
| 42483537 | Management of IgA nephropathy and the expanding role of immunomodulation. | Kidney Int Suppl (2011) | 2026 | https://conductscience.org/library/papers/42483537 | PubMed |
| 42421973 | Biomarkers predicting good prognosis among patients receiving immunosuppressive treatment in IgA nephropathy: the promising role of serum TGF-β1 and MCP-1. | Front Immunol | 2026 | https://conductscience.org/library/papers/42421973 | PubMed |
| 42415613 | Evolving therapeutic landscape of immunoglobulin A nephropathy: targeted immune pathways and novel therapies. | Kidney Res Clin Pract | 2026 | https://conductscience.org/library/papers/42415613 | PubMed |
| 42292450 | Real-world study of telitacicept in the treatment of IgA nephropathy. | Front Immunol | 2026 | https://conductscience.org/library/papers/42292450 | PubMed |
| 42243722 | FMultifunctional magnetic resonance imaging for the assessment of renal pathological alterations in IgA nephropathy. | BMC Nephrol | 2026 | https://conductscience.org/library/papers/42243722 | PubMed |
| 42216130 | Clinicopathological characteristics and renal outcomes of IgA nephropathy in systemic lupus erythematosus: a case report and systematic literature review. | BMC Nephrol | 2026 | https://conductscience.org/library/papers/42216130 | PubMed |
| 42087286 | Yi-Shen-Hua-Shi granule added to supportive care reduces proteinuria in IgA nephropathy: a multicenter randomized controlled trial. | Ren Fail | 2026 | https://conductscience.org/library/papers/42087286 | PubMed |
| 42032511 | Reshaping the therapeutic landscape of IgA nephropathy: a Bayesian network meta-analysis on the comparative efficacy and safety of immunosuppressants and targeted agents. | BMC Nephrol | 2026 | https://conductscience.org/library/papers/42032511 | PubMed |
| 41882420 | The epidemiology of kidney and urinary tract infections in pediatric chronic kidney disease: prevalence, risk factors and association with GFR decline in the Chronic Kidney Disease in Children Study. | Pediatr Nephrol | 2026 | https://conductscience.org/library/papers/41882420 | PubMed |
| 41840527 | Efficacy and safety of supportive and immunosuppressive therapies in the treatment of lgA nephropathy: a network Meta-analysis of randomized clinical trials. | BMC Nephrol | 2026 | https://conductscience.org/library/papers/41840527 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| REN | 5972 | PubTator's text mining | https://conductscience.org/library/genes/5972 |
Source NCBI Gene
Drugs3
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1200796 | ChEMBL |
| AZATHIOPRINE | CHEMBL1542 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1542 | ChEMBL |
| METHYLPREDNISOLONE | CHEMBL650 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL650 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28763548
GET https://conductscience.org/api/papers/v1/28763548/authors?page=2